Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 5, keine Gesamtzahl für „REYATAZ“
Suchtreffer
Begriffe & Kennungen
Reyataz · 4.5 · Effect on atazanavir and ritonavir exposure has not been studied. Expected: ↔ Atazanavir ↔ Ritonavir
Eintrag öffnenReyataz · 4.5 · Elbasvir AUC: ↑376% (↑307% ↑456%) Elbasvir Cmax: ↑315% (↑246% ↑397%) Elbasvir Cmin: ↑545% (↑451% ↑654%)
Eintrag öffnenReyataz · 4.5 · Elbasvir AUC: ↑376% (↑307% ↑456%) Elbasvir Cmax: ↑315% (↑246% ↑397%) Elbasvir Cmin: ↑545% (↑451% ↑654%)
Eintrag öffnenReyataz · 4.5 · Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir.
Eintrag öffnenReyataz · 4.5 · Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir. Sofosbuvir Sofosbuvir A
Eintrag öffnenReyataz · 4.5 · For co-administration of cutaneously administered corticosteroids sensitive to CYP3A inhibition, consult the S
Eintrag öffnenReyataz · 4.5 · For co-administration of cutaneously administered corticosteroids sensitive to CYP3A inhibition, consult the S
Eintrag öffnenReyataz · 4.5 · Grazoprevir concentrations were greatly increased when co-administered with atazanavir/ritonavir. Elbasvir 50
Eintrag öffnenReyataz · 4.5 · If genotyping is not feasible, full monitoring of safety and efficacy should be performed. Fluconazole 200 mg
Eintrag öffnenReyataz · 4.5 · If withdrawal of ritonavir is medically warranted under restrictive conditions (see section 4.4), special atte
Eintrag öffnenReyataz · 4.5 · In the majority of patients with at least one Therefore if the combination is functional CYP2C19 allele, a red
Eintrag öffnenReyataz · 4.5 · Interactions between atazanavir and other medicinal products, including those for which co- administration is
Eintrag öffnenReyataz · 4.5 · Interactions between atazanavir and other medicinal products, including those for which co- administration is
Eintrag öffnenReyataz · 4.5 · Medicinal products by Interaction Recommendations concerning co- therapeutic area administration ANTI-HCV AGEN
Eintrag öffnenReyataz · 4.5 · Medicinal products by Interaction Recommendations therapeutic area concerning co-administration ANTI-HCV AGENT
Eintrag öffnenReyataz · 4.5 · No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosi
Eintrag öffnenReyataz · 4.5 · No significant effect on atazanavir concentrations was observed. There was an increase in the maximum PR inter
Eintrag öffnenReyataz · 4.5 · No significant effect on atazanavir concentrations was observed. There was an increase in the maximum PR inter
Eintrag öffnenReyataz · 4.5 · No significant effect on didanosine and stavudine concentrations was observed.
Eintrag öffnenReyataz · 4.5 · No significant effect on didanosine and stavudine concentrations was observed. Didanosine (enteric coated Dida
Eintrag öffnen